Korean Beauty Brands Add Azelaic Acid, Blue Peptides to Lineups

Korean skincare formulators are broadening their ingredient rosters beyond PDRN, the salmon-derived compound that has anchored much of the category's recent growth, to include azelaic acid and a newer class the industry is calling blue peptides, according to a report from the Korean trade outlet Kagit, circulated via Google News.

The outlet frames the shift as a move toward what it terms 'ingredient innovation,' a phrase suggesting Korean brands are looking for the next formulation story to tell consumers now that PDRN has become widely available across price tiers.

"Ingredient innovation" — the phrase Kagit uses to describe the industry's pivot beyond PDRN toward azelaic acid and blue peptides.

What is Kagit reporting about K-beauty's ingredient shift?

Kagit's report identifies azelaic acid and blue peptides as the ingredients gaining traction as PDRN, short for polydeoxyribonucleotide, matures from a novelty into a category staple. The outlet's framing treats the move as evidence that Korean formulators are actively diversifying their active-ingredient toolkits rather than relying on a single hero compound, though the version of the report reviewed for this article did not name specific brands, launch dates, or sales figures tied to the transition.

What is PDRN and why has it dominated K-beauty?

PDRN is derived from the DNA of salmon or trout and has been used in Korean clinical and cosmetic settings for its association with tissue repair, a reputation that helped it cross over from dermatology offices into mass-market ampoules, serums, and sheet masks. Its rise mirrors earlier K-beauty ingredient cycles — snail mucin and centella asiatica among them — in which a compound with clinical or folk-remedy origins gets reformulated for shelf sale and marketed on its regenerative associations. Kagit's report treats PDRN's ubiquity as the backdrop against which brands are now searching for differentiation.

What are blue peptides?

The report groups a set of newer formulations under the label blue peptides, a term that, unlike retinol or hyaluronic acid, is not yet standardized across the industry. Peptides in general are short chains of amino acids that formulators incorporate to signal to skin cells or support the skin's structural proteins, and brands have historically differentiated peptide blends by naming conventions tied to color, origin, or targeted function. Kagit's coverage does not specify the exact composition or clinical backing behind the blue peptide formulations it references, and no independent verification of those claims was available in the source material for this article.

Why is azelaic acid part of the shift?

Azelaic acid has a longer track record outside K-beauty specifically. It is a dicarboxylic acid used in both prescription and over-the-counter formulations for acne, rosacea-related redness, and uneven skin tone, and it has been available in Western dermatology for years before its inclusion in the ingredient lists Kagit describes. Its addition to Korean formulations suggests brands are blending globally established actives with newer, more marketing-forward compounds like blue peptides rather than replacing one buzz ingredient with another single successor.

How should shoppers evaluate new K-beauty ingredient trends?

For consumers, a new ingredient name on a label is not the same as a new mechanism of action, and terms like blue peptides currently lack the regulatory or clinical consensus that governs better-documented actives. HTT News' own guide on evaluating skincare ingredient claims recommends checking concentration, patch-testing new actives, and being wary of ingredient names introduced primarily through marketing copy rather than peer-reviewed formulation data. Shoppers weighing PDRN-based products against newer azelaic acid or peptide-forward launches should also consider that azelaic acid has a more established dosing and side-effect profile than newer proprietary peptide blends, which can vary by manufacturer even when marketed under similar names.

Kagit's report signals a trend worth watching as more brands publish ingredient lists and clinical claims, but the specifics — concentrations, study designs, and which companies are leading the shift — were not detailed in the version of the report available for this article. Readers interested in tracking individual product claims should look for brands that publish concentration percentages and cite independent testing rather than relying on category buzzwords alone.